Fast Five Quiz: Systemic Treatments for Plaque Psoriasis

Chris G. Adigun, MD; William James, MD

Disclosures

December 21, 2021

The National Psoriasis Foundation has defined acceptable response criteria as an achievement of BSA 3% or less or a BSA improvement of 75% or greater from baseline, and noted the importance of establishing treatment goals to improve the care of patients with psoriasis.

Regardless of the type of therapy being initiated, psoriasis experts agree that a follow-up evaluation should be performed 3 months after treatment initiation to assess tolerability and clinical response. Regular follow-up evaluations should be performed every 6 months thereafter.

Escalation to a biologic medication may be considered for patients who have an inadequate response to oral systemic agents at any point during treatment.

For additional information, refer to the British Association of Dermatologists guidelines for biologic therapy for psoriasis, the Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics, and the Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.

Learn more about systemic and biologic treatments for plaque psoriasis.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....